



Q & M DENTAL GROUP (SINGAPORE) LIMITED
(Company Registration Number 200800507R)
(Incorporated in the Republic of Singapore)

UPDATE FROM ACUMEN DIAGNOSTICS PTE. LTD.

IN RELATION TO DR. ONG SIEW HWA

The board of directors (the “**Board**” or “**Directors**”) of Q & M Dental Group (Singapore) Limited (the “**Company**”, and collectively with its subsidiaries, the “**Group**”) wishes to announce that the board of directors (“**Acumen Board**”) of Acumen Diagnostics Pte. Ltd. (“**Acumen**”), a subsidiary of the Company, has placed Dr. Ong Siew Hwa (“**Dr. Ong**”), the chief executive officer of Acumen, on a leave of absence. The Board understands that this is to facilitate investigations by the Acumen Board into Dr Ong’s acquisition of an indirect interest in the assets of a supplier of Acumen and ancillary issues arising from it. Dr. Ong is also an executive director of Aoxin Q & M Dental Group Limited, an associated company of the Group.

The Board notes that Dr. Ong has objected to being placed on a leave of absence by the Acumen Board. She does not agree that there is any cause for investigation into her acquisition and she has provided her explanation to the Acumen Board. The Acumen Board has disagreed with her position and is therefore investigating this matter. The Board will work with the Acumen Board and its professionals on the review of the investigations.

During this period, the Acumen Board has appointed Mr. Lua Chong Hui (Joseph) (“**Mr. Lua**”) to assume Dr. Ong’s responsibilities to ensure that any disruption to Acumen’s business and operations are kept to the minimum. Mr. Lua’s background, education, and training are in molecular biology. He has prior experience working in a translational scientific lab at Singapore’s National Heart Centre, where he contributed to the development of pioneering treatments for human heart diseases. Since 2020, he has assisted Acumen’s management team in the management and operations of Acumen. Accordingly, the Acumen Board has determined that he is suitable for this appointment as he (i) possesses the necessary knowledge and skillset to run a molecular laboratory, and (ii) is familiar with the staff and operations of Acumen.

The Board is of the view that the matters stated herein are not likely to have any material adverse impact on the Group’s operations and financial performance. Further, barring unforeseen circumstances, the Board is of the view that Dr. Ong’s leave of absence is not expected to have a material adverse impact on the Group’s business and operations.

The Company will make further announcements(s) to keep shareholders updated as and when there are material developments to the matter. **Shareholders are advised to exercise caution when dealing in the securities of the Company and to refrain from taking any action in relation to their shares which may be prejudicial to their interests.**

By Order of the Board

Ng Sook Hwa
Chief Financial Officer
29 June 2024